<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02127281</url>
  </required_header>
  <id_info>
    <org_study_id>CCF 14-273</org_study_id>
    <nct_id>NCT02127281</nct_id>
  </id_info>
  <brief_title>Evaluation of Wound Management With Negative Pressure Dressing Versus Standard Dressing After Revision Arthroplasty.</brief_title>
  <official_title>Randomized Controlled Trial of Wound Management With Negative Pressure Dressing Versus Standard Dressing After Knee and Hip Revision Arthroplasty.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KCI USA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of a negative pressure wound therapy
      (NPWT) system after revision total knee and hip arthroplasty in patients at high risk for
      infection. It is hypothesized that the use of NPWT system (i.e., Prevena) in high risk
      patients prevents wound complications and decreases reoperation rates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One of the primary causes of un-planned readmission following lower extremity arthroplasty
      procedures is infection. Continuous wound drainage poses a serious risk for infection and is
      often initially treated with absorbent dressings and/or oral antibiotics. Comorbidities such
      as obesity, diabetes and tobacco abuse predisposes to wound complications and therefore
      infection after these procedures. NPWT has proven to be effective for postoperative drainage
      and decreases the risk for infection or further reoperation. This prospective randomized
      trial will involve 160 patients at high risk for infection undergoing revision total knee or
      hip arthroplasty; 80 patients will be randomly selected to be treated with the NPWT system
      (Prevena) and randomly selected to be treated with the current standard of care wound
      dressing (control group). Patients will be enrolled at a single site of the Cleveland Clinic
      Health System (Main Campus).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">June 30, 2017</completion_date>
  <primary_completion_date type="Actual">April 24, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Wound Complications</measure>
    <time_frame>Within 90 days after surgery</time_frame>
    <description>Any wound complications including but not limited to drainage, blisters, cellulitis, superficial infection, and deep infection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Re-operation Rates</measure>
    <time_frame>Within 90 days after surgery</time_frame>
    <description>Number of patients who required re-operations that were related to the revision arthroplasty and occurred within 90 days of the revision</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Readmission Rates</measure>
    <time_frame>Within 90 days after surgery</time_frame>
    <description>Number of patients who had hospital readmission(s) related to the revision surgery that occurred within 90 days of revision</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Knee Flexion</measure>
    <time_frame>4 weeks postoperative</time_frame>
    <description>Mean knee flexion (degrees) at 4 weeks postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOOS and KOOS Scores at 90 Days Postoperatively</measure>
    <time_frame>90 days postoperative</time_frame>
    <description>Mean Hip Osteoarthritis Outcome Score (HOOS), Knee Osteoarthritis Outcomes Score (KOOS) at 90 days postoperatively. Presented as subscores, including activities of daily living (ADL), pain, quality of life (QOL), symptoms, sports and recreation. All subscores range from 0-100, with 0 being the worst score and 100 being the best possible score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timed-up-and-go Test</measure>
    <time_frame>4 weeks postoperatively</time_frame>
    <description>Median Timed-up-and-go test (seconds)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hip Range of Motion (Flexion)</measure>
    <time_frame>4 weeks postoperative</time_frame>
    <description>Mean hip range of motion (flexion, in degrees) at 4 weeks postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VR-12 Questionnaire</measure>
    <time_frame>90 days postoperatively</time_frame>
    <description>Mean VR-12 scores, presented as 2 composite scores physical component summary (PCS) and mental component summary (MCS). Physical Component Score (PCS): Provides greater emphasis on questions about general health, physical functioning and role playing and bodily pain. Mental Component Score (MCS): Provides greater emphasis on questions about role-emotional, vitality/mental health and social functioning. PCS and MCS summary scores are standardized using a z-score transformation and normed to a U.S. population (based on a 1990 norm) of a score of 50 and a standard deviation of 10. Higher MCS and PCS scores reflect better overall physical and mental health, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hip Range of Motion</measure>
    <time_frame>4 weeks postoperative</time_frame>
    <description>Median hip range of motion (extension, in degrees) at 4 weeks postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee Extension</measure>
    <time_frame>4 weeks postoperative</time_frame>
    <description>Median knee extension (degrees) at 4 weeks postoperatively</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Prosthesis-related Infections</condition>
  <condition>Wound Complications</condition>
  <condition>Joint Diseases</condition>
  <condition>Musculoskeletal Diseases</condition>
  <arm_group>
    <arm_group_label>Prevena</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prevena NPWT system will be used immediately following surgery and continue postoperatively until hospital discharge (expected average of 4 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>A standard of care sterile wound dressing will be placed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Prevena</intervention_name>
    <description>Device will be applied at end of procedure over closed incision.</description>
    <arm_group_label>Prevena</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled revision Total Hip or Knee Arthroplasty Procedure

          -  Presence of one of the following: body mass index (BMI) greater than 35, use of blood
             thinners other than acetylsalicylic acid (ASA) after surgery, peripheral vascular
             disease, depression, diabetes mellitus, current tobacco use, history of prior
             infection, current use of immunomodulators or steroids, current history of cancer or
             hematological malignancy, rheumatoid arthritis, renal failure or dialysis,
             malnutrition, liver disease, transplant status, or HIV.

        Exclusion Criteria:

          -  Patient lives &gt;100 miles from hospital

          -  Patient is &lt; 18 years old

          -  Silver allergy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Higuera-Rueda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>440195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hansen E, Durinka JB, Costanzo JA, Austin MS, Deirmengian GK. Negative pressure wound therapy is associated with resolution of incisional drainage in most wounds after hip arthroplasty. Clin Orthop Relat Res. 2013 Oct;471(10):3230-6. doi: 10.1007/s11999-013-2937-3.</citation>
    <PMID>23539123</PMID>
  </reference>
  <reference>
    <citation>Bozic KJ, Kurtz SM, Lau E, Ong K, Chiu V, Vail TP, Rubash HE, Berry DJ. The epidemiology of revision total knee arthroplasty in the United States. Clin Orthop Relat Res. 2010 Jan;468(1):45-51. doi: 10.1007/s11999-009-0945-0. Epub 2009 Jun 25.</citation>
    <PMID>19554385</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2014</study_first_submitted>
  <study_first_submitted_qc>April 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2014</study_first_posted>
  <results_first_submitted>August 17, 2017</results_first_submitted>
  <results_first_submitted_qc>March 22, 2018</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 26, 2018</results_first_posted>
  <last_update_submitted>March 22, 2018</last_update_submitted>
  <last_update_submitted_qc>March 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Carlos Higuera-Rueda</investigator_full_name>
    <investigator_title>Staff, Adult Reconstruction</investigator_title>
  </responsible_party>
  <keyword>Revision total knee arthroplasty</keyword>
  <keyword>Revision total hip arthroplasty</keyword>
  <keyword>Negative pressure wound therapy system (NPWT)</keyword>
  <keyword>Drainage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Joint Diseases</mesh_term>
    <mesh_term>Musculoskeletal Diseases</mesh_term>
    <mesh_term>Prosthesis-Related Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Prevena</title>
          <description>Prevena NPWT system will be used immediately following surgery and continue postoperatively until hospital discharge (expected average of 4 days).
Prevena: Device will be applied at end of procedure over closed incision.</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>A standard of care sterile wound dressing will be placed.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Prevena</title>
          <description>Prevena NPWT system will be used immediately following surgery and continue postoperatively until hospital discharge (expected average of 4 days).
Prevena: Device will be applied at end of procedure over closed incision.</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>A standard of care sterile wound dressing will be placed.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="80"/>
            <count group_id="B2" value="80"/>
            <count group_id="B3" value="160"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" lower_limit="27" upper_limit="90"/>
                    <measurement group_id="B2" value="65" lower_limit="37" upper_limit="93"/>
                    <measurement group_id="B3" value="65" lower_limit="27" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-white</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.9" lower_limit="20.2" upper_limit="53.7"/>
                    <measurement group_id="B2" value="33.4" lower_limit="20.4" upper_limit="58.7"/>
                    <measurement group_id="B3" value="32.7" lower_limit="20.2" upper_limit="58.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Charlson comorbidity index</title>
          <description>The Charlson Comorbidity Index contains 19 categories of comorbidity and predicts the ten-year mortality for a patient who may have a range of co-morbid conditions. Each condition is assigned with a score of 1,2,3 or 6 depending on the risk of dying associated with this condition. A higher score indicated a higher level of illness.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>American Society of Anesthesiologists score</title>
          <description>American Society of Anesthesiologists score a global score that assesses the physical status of patients before surgery, based on five classes 1 to 5. A higher score indicated a higher level of illness.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>=&lt;2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Wound Complications</title>
        <description>Any wound complications including but not limited to drainage, blisters, cellulitis, superficial infection, and deep infection.</description>
        <time_frame>Within 90 days after surgery</time_frame>
        <population>80 patients allocated to the prevena arm, and 79 patients were analyzed: 1 patient lost to follow-up; also, 1 patient had the prevena removed early but included as an intent to treat.
80 patients allocated to control arm, with 80 patients analyzed. 6 patients did not receive the allocated treatment but were included for intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Prevena</title>
            <description>Prevena NPWT system will be used immediately following surgery and continue postoperatively until hospital discharge (expected average of 4 days).
Prevena: Device will be applied at end of procedure over closed incision.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>A standard of care sterile wound dressing will be placed.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Wound Complications</title>
          <description>Any wound complications including but not limited to drainage, blisters, cellulitis, superficial infection, and deep infection.</description>
          <population>80 patients allocated to the prevena arm, and 79 patients were analyzed: 1 patient lost to follow-up; also, 1 patient had the prevena removed early but included as an intent to treat.
80 patients allocated to control arm, with 80 patients analyzed. 6 patients did not receive the allocated treatment but were included for intent to treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Re-operation Rates</title>
        <description>Number of patients who required re-operations that were related to the revision arthroplasty and occurred within 90 days of the revision</description>
        <time_frame>Within 90 days after surgery</time_frame>
        <population>80 patients allocated to the prevena arm, and 79 patients were analyzed: 1 patient lost to follow-up; also, 1 patient had the prevena removed early but included as an intent to treat.
80 patients allocated to control arm, with 80 patients analyzed. 6 patients did not receive the allocated treatment but were included for intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Prevena</title>
            <description>Prevena NPWT system will be used immediately following surgery and continue postoperatively until hospital discharge (expected average of 4 days).
Prevena: Device will be applied at end of procedure over closed incision.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>A standard of care sterile wound dressing will be placed.</description>
          </group>
        </group_list>
        <measure>
          <title>Re-operation Rates</title>
          <description>Number of patients who required re-operations that were related to the revision arthroplasty and occurred within 90 days of the revision</description>
          <population>80 patients allocated to the prevena arm, and 79 patients were analyzed: 1 patient lost to follow-up; also, 1 patient had the prevena removed early but included as an intent to treat.
80 patients allocated to control arm, with 80 patients analyzed. 6 patients did not receive the allocated treatment but were included for intent to treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Readmission Rates</title>
        <description>Number of patients who had hospital readmission(s) related to the revision surgery that occurred within 90 days of revision</description>
        <time_frame>Within 90 days after surgery</time_frame>
        <population>80 patients allocated to the prevena arm, and 79 patients were analyzed: 1 patient lost to follow-up; also, 1 patient had the prevena removed early but included as an intent to treat.
80 patients allocated to control arm, with 80 patients analyzed. 6 patients did not receive the allocated treatment but were included for intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Prevena</title>
            <description>Prevena NPWT system will be used immediately following surgery and continue postoperatively until hospital discharge (expected average of 4 days).
Prevena: Device will be applied at end of procedure over closed incision.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>A standard of care sterile wound dressing will be placed.</description>
          </group>
        </group_list>
        <measure>
          <title>Readmission Rates</title>
          <description>Number of patients who had hospital readmission(s) related to the revision surgery that occurred within 90 days of revision</description>
          <population>80 patients allocated to the prevena arm, and 79 patients were analyzed: 1 patient lost to follow-up; also, 1 patient had the prevena removed early but included as an intent to treat.
80 patients allocated to control arm, with 80 patients analyzed. 6 patients did not receive the allocated treatment but were included for intent to treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Knee Flexion</title>
        <description>Mean knee flexion (degrees) at 4 weeks postoperatively</description>
        <time_frame>4 weeks postoperative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prevena</title>
            <description>Prevena NPWT system will be used immediately following surgery and continue postoperatively until hospital discharge (expected average of 4 days).
Prevena: Device will be applied at end of procedure over closed incision.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>A standard of care sterile wound dressing will be placed.</description>
          </group>
        </group_list>
        <measure>
          <title>Knee Flexion</title>
          <description>Mean knee flexion (degrees) at 4 weeks postoperatively</description>
          <units>degrees</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.7" spread="21.6"/>
                    <measurement group_id="O2" value="88.9" spread="23.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HOOS and KOOS Scores at 90 Days Postoperatively</title>
        <description>Mean Hip Osteoarthritis Outcome Score (HOOS), Knee Osteoarthritis Outcomes Score (KOOS) at 90 days postoperatively. Presented as subscores, including activities of daily living (ADL), pain, quality of life (QOL), symptoms, sports and recreation. All subscores range from 0-100, with 0 being the worst score and 100 being the best possible score.</description>
        <time_frame>90 days postoperative</time_frame>
        <population>The number analyzed is different from the overall number because there are separate questionnaires for Hip and Knee, and there were Hips and Knees in both the Prevena and Control groups</population>
        <group_list>
          <group group_id="O1">
            <title>Prevena</title>
            <description>Prevena NPWT system will be used immediately following surgery and continue postoperatively until hospital discharge (expected average of 4 days).
Prevena: Device will be applied at end of procedure over closed incision.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>A standard of care sterile wound dressing will be placed.</description>
          </group>
        </group_list>
        <measure>
          <title>HOOS and KOOS Scores at 90 Days Postoperatively</title>
          <description>Mean Hip Osteoarthritis Outcome Score (HOOS), Knee Osteoarthritis Outcomes Score (KOOS) at 90 days postoperatively. Presented as subscores, including activities of daily living (ADL), pain, quality of life (QOL), symptoms, sports and recreation. All subscores range from 0-100, with 0 being the worst score and 100 being the best possible score.</description>
          <population>The number analyzed is different from the overall number because there are separate questionnaires for Hip and Knee, and there were Hips and Knees in both the Prevena and Control groups</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HOOS ADL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.1" spread="23.9"/>
                    <measurement group_id="O2" value="66.4" spread="25.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HOOS Pain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.4" spread="23.7"/>
                    <measurement group_id="O2" value="70.3" spread="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HOOS QOL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.7" spread="21.3"/>
                    <measurement group_id="O2" value="37.9" spread="26.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HOOS Symptoms</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.3" spread="17.4"/>
                    <measurement group_id="O2" value="70.2" spread="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KOOS ADL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.5" spread="24.7"/>
                    <measurement group_id="O2" value="54.3" spread="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KOOS pain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.1" spread="24.9"/>
                    <measurement group_id="O2" value="55.8" spread="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KOOS symptoms</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.9" spread="18.1"/>
                    <measurement group_id="O2" value="55.9" spread="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HOOS and KOOS Scores at 90 Days Postoperatively</title>
        <description>Mean Hip Osteoarthritis Outcome Score (HOOS), Knee Osteoarthritis Outcomes Score (KOOS) at 90 days postoperatively. Presented as subscores, including activities of daily living (ADL), pain, quality of life (QOL), symptoms, sports and recreation. All subscores range from 0-100, with 0 being the worst score and 100 being the best possible score.</description>
        <time_frame>90 days postoperative</time_frame>
        <population>The number analyzed is different from the overall number because there are separate questionnaires for Hip and Knee, and there were Hips and Knees in both the Prevena and Control groups</population>
        <group_list>
          <group group_id="O1">
            <title>Prevena</title>
            <description>Prevena NPWT system will be used immediately following surgery and continue postoperatively until hospital discharge (expected average of 4 days).
Prevena: Device will be applied at end of procedure over closed incision.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>A standard of care sterile wound dressing will be placed.</description>
          </group>
        </group_list>
        <measure>
          <title>HOOS and KOOS Scores at 90 Days Postoperatively</title>
          <description>Mean Hip Osteoarthritis Outcome Score (HOOS), Knee Osteoarthritis Outcomes Score (KOOS) at 90 days postoperatively. Presented as subscores, including activities of daily living (ADL), pain, quality of life (QOL), symptoms, sports and recreation. All subscores range from 0-100, with 0 being the worst score and 100 being the best possible score.</description>
          <population>The number analyzed is different from the overall number because there are separate questionnaires for Hip and Knee, and there were Hips and Knees in both the Prevena and Control groups</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HOOS sports/rec</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8" lower_limit="6.3" upper_limit="34.4"/>
                    <measurement group_id="O2" value="21.9" lower_limit="6.3" upper_limit="48.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KOOS QOL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.8" lower_limit="25" upper_limit="62.5"/>
                    <measurement group_id="O2" value="34.4" lower_limit="14.1" upper_limit="43.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KOOS sports/rec</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="25"/>
                    <measurement group_id="O2" value="10" lower_limit="0" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Timed-up-and-go Test</title>
        <description>Median Timed-up-and-go test (seconds)</description>
        <time_frame>4 weeks postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prevena</title>
            <description>Prevena NPWT system will be used immediately following surgery and continue postoperatively until hospital discharge (expected average of 4 days).
Prevena: Device will be applied at end of procedure over closed incision.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>A standard of care sterile wound dressing will be placed.</description>
          </group>
        </group_list>
        <measure>
          <title>Timed-up-and-go Test</title>
          <description>Median Timed-up-and-go test (seconds)</description>
          <units>seconds</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="14.3" upper_limit="37"/>
                    <measurement group_id="O2" value="24.2" lower_limit="15" upper_limit="39.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hip Range of Motion (Flexion)</title>
        <description>Mean hip range of motion (flexion, in degrees) at 4 weeks postoperatively</description>
        <time_frame>4 weeks postoperative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prevena</title>
            <description>Prevena NPWT system will be used immediately following surgery and continue postoperatively until hospital discharge (expected average of 4 days).
Prevena: Device will be applied at end of procedure over closed incision.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>A standard of care sterile wound dressing will be placed.</description>
          </group>
        </group_list>
        <measure>
          <title>Hip Range of Motion (Flexion)</title>
          <description>Mean hip range of motion (flexion, in degrees) at 4 weeks postoperatively</description>
          <units>degrees</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.6" spread="22.9"/>
                    <measurement group_id="O2" value="75.3" spread="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VR-12 Questionnaire</title>
        <description>Mean VR-12 scores, presented as 2 composite scores physical component summary (PCS) and mental component summary (MCS). Physical Component Score (PCS): Provides greater emphasis on questions about general health, physical functioning and role playing and bodily pain. Mental Component Score (MCS): Provides greater emphasis on questions about role-emotional, vitality/mental health and social functioning. PCS and MCS summary scores are standardized using a z-score transformation and normed to a U.S. population (based on a 1990 norm) of a score of 50 and a standard deviation of 10. Higher MCS and PCS scores reflect better overall physical and mental health, respectively.</description>
        <time_frame>90 days postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prevena</title>
            <description>Prevena NPWT system will be used immediately following surgery and continue postoperatively until hospital discharge (expected average of 4 days).
Prevena: Device will be applied at end of procedure over closed incision.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>A standard of care sterile wound dressing will be placed.</description>
          </group>
        </group_list>
        <measure>
          <title>VR-12 Questionnaire</title>
          <description>Mean VR-12 scores, presented as 2 composite scores physical component summary (PCS) and mental component summary (MCS). Physical Component Score (PCS): Provides greater emphasis on questions about general health, physical functioning and role playing and bodily pain. Mental Component Score (MCS): Provides greater emphasis on questions about role-emotional, vitality/mental health and social functioning. PCS and MCS summary scores are standardized using a z-score transformation and normed to a U.S. population (based on a 1990 norm) of a score of 50 and a standard deviation of 10. Higher MCS and PCS scores reflect better overall physical and mental health, respectively.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" spread="9.6"/>
                    <measurement group_id="O2" value="31.5" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.2" spread="12.3"/>
                    <measurement group_id="O2" value="46.6" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hip Range of Motion</title>
        <description>Median hip range of motion (extension, in degrees) at 4 weeks postoperatively</description>
        <time_frame>4 weeks postoperative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prevena</title>
            <description>Prevena NPWT system will be used immediately following surgery and continue postoperatively until hospital discharge (expected average of 4 days).
Prevena: Device will be applied at end of procedure over closed incision.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>A standard of care sterile wound dressing will be placed.</description>
          </group>
        </group_list>
        <measure>
          <title>Hip Range of Motion</title>
          <description>Median hip range of motion (extension, in degrees) at 4 weeks postoperatively</description>
          <units>degrees</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Knee Extension</title>
        <description>Median knee extension (degrees) at 4 weeks postoperatively</description>
        <time_frame>4 weeks postoperative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prevena</title>
            <description>Prevena NPWT system will be used immediately following surgery and continue postoperatively until hospital discharge (expected average of 4 days).
Prevena: Device will be applied at end of procedure over closed incision.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>A standard of care sterile wound dressing will be placed.</description>
          </group>
        </group_list>
        <measure>
          <title>Knee Extension</title>
          <description>Median knee extension (degrees) at 4 weeks postoperatively</description>
          <units>degrees</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="O2" value="5" lower_limit="0" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>90 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Prevena</title>
          <description>Prevena NPWT system will be used immediately following surgery and continue postoperatively until hospital discharge (expected average of 4 days).
Prevena: Device will be applied at end of procedure over closed incision.</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>A standard of care sterile wound dressing will be placed.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Venous Thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Prosthetic Joint Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Readmission</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="80"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Reoperation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dislocation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>mild edema (lung)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Wound drainage</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="80"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alison K. Klika, MS, Research Manager, Department of Orthopaedic Surgery</name_or_title>
      <organization>Cleveland Clinic</organization>
      <phone>(216) 444-4954</phone>
      <email>klikaa@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

